Presentations at national events

2024

  • Gallego Rudolf J, Qiu T, Javanray M, Wiesman A, Fajardo-Valdez A, Baillet S, Villeneuve S, for the PREVENT-AD Research Group. (2024) Functional and structural connectivity predict patterns of longitudinal tau accumulation in asymptomatic individuals expressing Aβ pathology. QBIN Scientific Day 2024. Montreal, Canada. Oral Presentation [PDF]
  • Hall B, Qiu T, Fajardo-Valdez A, Pichet Binette A, Descoteaux A, Villeneuve S, for the PREVENT-AD Research Group. (2024) Sex differences in the associations between plasma GFAP and fornix white matter properties in the PREVENT-AD cohort. QBIN Scientific Day 2024. Montreal, Canada. Oral Presentation [PDF]
  • Javanray M, St-Onge F, Bellec P, Misic B, Soucy J-P, Villeneuve S, for the PREVENT-AD Research Group. (2024) Brain functional flexibility and its relationship to the preclinical stage of Alzheimer’s disease. QBIN Scientific Day 2024. Montreal, Canada. Oral Presentation [PDF]
  • Qiu T, Liu Z-Q, Gallego Rudolf J, Valcourt Caron A, Soucy J-P, Spreng RN, Descoteaux M, Villeneuve S, for the PREVENT-AD Research Group. (2024) Associations between amyloid-β and tau pathology, structural brain properties, and cognitive performance during preclinical and prodromal Alzheimer’s disease. QBIN Scientific Day 2024. Montreal, Canada. Oral Presentation [PDF]
  • Gallego Rudolf J, Wiesman A, Pichet Binette A, Baillet S, Villeneuve S, PREVENT-AD Research Group. (2024) Neurophysiological markers for predicting MCI progression in asymptomatic older adults. Healthy Brains Healthy Lives 2024 Symposium. Montreal, Canada. Oral Presentation
  • Metz A, Zeighami Y, Ducharme S, Villeneuve S, Dadar M. (2024) Association between DBM-derived atrophy patterns and cognition in frontotemporal dementia variants. Healthy Brains Healthy Lives 2024 Symposium. Montreal, Canada. [abstract]

2023

  • Gallego Rudolf J, Wiesman A, Baillet S, Villeneuve S, for the PREVENT-AD Research Group. (2023) Neurophysiological activity linked to Aβ and tau relate to MCI progression. QBIN Scientific Day 2023. Québec, Canada. Oral Presentation [PDF]
  • Mohammediyan B, Baril A-A, St-Onge F, Ourry V, Carrier J, Soucy J-P, Breitner JCS, Poirier J, Villeneuve S, for the PREVENT-AD Research Group. (2023) Longitudinal bidirectional associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adults. QBIN Scientific Day 2023. Québec, Canada. Oral Presentation [PDF]
  • St-Onge F, Pichet Binette A, Chapleau M, Breitner JCS, Villeneuve S. (2023) Differential regional tau burden and association to cognition in Alzheimer’s disease. QBIN Scientific Day 2023. Québec, Canada. Oral Presentation [PDF]

2022

  • Yakoub Y, Ashton NJ, Strikwerda-Brown, C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer P-F, St-Onge F, Schöll M, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2022) Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease. HBHL Research Day. Montreal, Canada. [PDF]
  • St-Onge F, Javanray M, Pichet Binette A, Strikwerda-Brown C, Remz J, Misic B, Vachon-Presseau E, Villeneuve S. (2022) Unique functional fingerprints through the lifespan. HBHL Research Day. Montreal, Canada. Oral Presentation [PDF]
  • St-Onge F, Javanray M, Pichet Binette A, Strikwerda-Brown C, Remz J, Misic B, Vachon-Presseau E, Villeneuve S. (2022) Unique features of functional connectivity fingerprints during aging. QBIN Scientific Day. Sherbrooke, Canada. [PDF]
  • Gallego Rudolf J, Wiesman A, Pichet Binette A, Villeneuve S, Baillet S. (2022) Electrophysiological markers of early Alzheimer’s disease proteinopathy in the human brain. QBIN Scientific Day. Sherbrooke, Canada. [PDF]
  • Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac P, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer P-F, St-Onge F, Schöll M, Breitner J, Zetterberg H, Blennow K, Poirier J, Villeneuve S. (2022) Evaluation of Longitudinal Plasma Biomarkers Trajectories across Cognitively Unimpaired Older Adults at Risk of Alzheimer’s Disease. QBIN Scientific Day. Sherbrooke, Canada. [PDF]
  • Qiu T, Villeneuve S, PREVENT-AD Research Group. (2022) Diffusion MRI subnetwork properties is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia. QBIN Scientific Day. Sherbrooke, Canada. [PDF]
  • Mohammediyan B, Baril A-A, Carrier J, Villeneuve S, PREVENT-AD Research Group. (2022) Sleep Quality and Alzheimer’s Disease (AD) Pathology in At-Risk Cognitively Unimpaired Adults. QBIN Scientific Day. Sherbrooke, Canada. [PDF]
  • Boutin S, Brambati S, Villeneuve S, PREVENT-AD Research Group. (2022) Detecting People at Risk of Alzheimer’s Disease: Amyloid and Tau Burden and Name Recall Impairments in Cognitively Unimpaired Individuals. QBIN Scientific Day. Sherbrooke, Canada. [PDF]

2020

  • Ozlen H, Pichet Binette A, Köbe T, Meyer P-F, Villeneuve S, PREVENT-AD Research Group. (2020) Widespread amyloid is necessary to detect tau-PET signal beyond the entorhinal cortex and cognitive decline. 12th QBIN Scientific Day. Montreal, Canada. [PDF]
  • Pichet Binette A, Theaud G, Rheault F, Gonneaud J, Roy M, Poirier J, Descoteaux M, Villeneuve S, PREVENT-AD Research Group. (2020) Amyloid and tau PET burden are associated with white matter bundle abnormalities in asymptomatic individuals at risk of Alzheimer’s disease. 12th QBIN Scientific Day. Montreal, Canada. [PDF]
  • St-Onge F, Remz J, Pichet Binette A, Villeneuve S, PREVENT-AD Research Group. (2020) Fingerprinting functional connectivity of individuals at risk of developing Alzheimer’s disease. 12th QBIN Scientific Day. Montreal, Canada. [PDF]

2019

  • Köbe T, Gonneaud J, Pichet Binette A, Meyer P-F, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2019) Vascular drugs intake influences the association between vascular and amyloid burden in asymptomatic individuals at risk for Alzheimer’s disease. 11th QBIN Scientific Day. Montreal, Canada.
  • Meyer P-F, Pichet Binette A, Breitner JC, Villeneuve S, PREVENT-AD research group. (2019) Cerebrospinal fluid and PET measures of tau pathology reflect different states of AD pathophysiological progression. 11th QBIN Scientific Day. Montreal, Canada. [PDF]
  • Lovland L, Jones R, Pichet Binette A, Villeneuve S, Marchant N, PREVENT-AD research group. (2019) Repetitive negative thinking predicts decline in memory and other cognitive functions. Alzheimer’s Society Conference. London, UK.

2018

  • Pichet Binette A*, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2018) Neuropsychiatric burden is related to increased amyloid but not tau deposition in late-middle-aged cognitively normal individuals with a family history of Alzheimer’s disease. NeuroQAM Annual Research Day. Montreal, Canada. * Prize; Oral Presentation
  • Gonneaud J *, Vachon-Presseau E*, Baria A, Pichet Binette A, Benzinger T, Morris J, Bateman R, Breitner J, Poirier J, Villeneuve S, for the PREVENT-AD research group. (2018) The preclinical phase of autosomal dominant Alzheimer’s disease is characterized by accelerated brain aging. Montreal Neurological Institute Brain Imaging Center Retreat. Montreal, Canada. * Prize; Oral Presentation [PDF]
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Poirier J, Rosa-Neto P, Breitner JC, Villeneuve S, for the PREVENT-AD research group. (2018) Early increase in tau-PET signal is associated with Aβ burden, CSF p-tau levels and cognition in cognitively normal older adults. Brenda Milner Centennial Symposium. Montreal, Canada.
  • Gonneaud J, Bedetti C, Pichet Binette A, Benzinger T, Morris R, Bateman R, Poirier J, Breitner JC, Villeneuve S, DIAN Study Group, Prevent-AD Research Group. (2018) Genetic and environmental factors are differentially related to Aβ burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer’s disease. Brenda Milner Centennial Symposium. Montreal, Canada.
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Poirier J, Rosa-Neto P, Breitner JC, Villeneuve S, for the PREVENT-AD research group. (2018) Early increase in tau-PET signal is associated with Aβ burden, CSF p-tau levels and cognition in cognitively normal older adults. Douglas Research Day. Montreal, Canada.
  • Pichet Binette A*, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2018) Neuropsychiatric burden is related to increased amyloid but not tau deposition in late-middle-aged cognitively normal individuals with a family history of Alzheimer’s disease. Douglas Research Day. Montreal, Canada. * Prize
  • Gonneaud J, Bedetti C, Pichet Binette A, Benzinger T, Morris R, Bateman R, Poirier J, Breitner JC, Villeneuve S, DIAN Study Group, Prevent-AD Research Group. (2018) Genetic and environmental factors are differentially related to Aβ burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer’s disease. Douglas Research Day. Montreal, Canada. Oral Presentation
  • Pichet Binette A*, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2018) Neuropsychiatric burden is related to increased amyloid but not tau deposition in late-middle-aged cognitively normal individuals with a family history of Alzheimer’s disease. Canadian Student Health Research Forum. Winnipeg, Canada. * Prize
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Poirier J, Rosa-Neto P, Breitner JC, Villeneuve S, for the PREVENT-AD research group. (2018) Early increase in tau-PET signal is associated with Aβ burden, CSF p-tau levels and cognition in cognitively normal late-middle-aged adults. 3rd Annual Neurosymposium. Montreal, Canada.
  • McSweeney M, Pichet Binette A, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Daoust L-A, Labonté A, Poirier J, Rosa-Neto P, Breitner JC, Villeneuve S, for the PREVENT-AD research group. (2018) Early increase in tau-PET signal is associated with Aβ burden, CSF p-tau levels and cognition in cognitively normal late-middle-aged adults. 10th Annual Quebec Bio-imaging Network Research Day. Montreal, Canada.
  • Pichet Binette A, Vachon-Presseau E, Gonneaud J, Marchant N, Bellec P, Breitner JC, Villeneuve S, PREVENT-AD Research Group. (2018) Neuropsychiatric burden is related to increased amyloid but not tau deposition in late-middle-aged cognitively normal individuals with a family history of Alzheimer’s disease. 10th Annual Quebec Bio-imaging Network Research Day. Montreal, Canada.
  • Gonneaud J, Bedetti C, Pichet Binette A, Benzinger T, Morris R, Bateman R, Poirier J, Breitner JC, Villeneuve S, DIAN Study Group, Prevent-AD Research Group. (2018) Genetic and environmental factors are differentially related to Aβ burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer’s disease. 10th Annual Quebec Bio-imaging Network Research Day. Montreal, Canada.

2016

  • Pichet Binette A, Vogel JW, Fonov V, Tremblay-Mercier J, Madjar C, Breitner J, Collins L, Poirier J, Villeneuve S, PREVENT-AD Research Group. (2016) High CSF tau is related to reduced hippocampal volume and subjective cognitive decline in healthy elderly with amyloid pathology. Douglas Research Day. Oral Presentation [PDF]
  • Vogel JW, Orban P, Pichet Binette A, La Joie R, Savard M, Tam A, Breitner J, Bellec P, Villeneuve S, PREVENT-AD. (2016) Regional gray matter volume and default mode network connectivity are associated with age relative to parental symptom onset in sporadic Alzheimer’s disease. Montreal, Canada. [PDF]